A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

被引：51

作者：

Kelleher, AD ^{[1
]}

Puls, RL

Bebbington, M

Boyle, D

Ffrench, R

Kent, SJ

Kippax, S

Purcell, DFJ

Thomson, S

Wand, H

Cooper, DA

Emery, S

机构：

[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia

[2] St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia

[3] St Vincents Hosp, Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia

[4] Australian Federat AIDS Org, Newtown, NSW, Australia

[5] CSIRO, Div Livestock Ind, Australian Anim Hlth Lab, Geelong, Vic, Australia

[6] Sydney Childrens Hosp, Westfield Labs, Randwick, NSW, Australia

[7] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia

[8] Univ New S Wales, Natl Ctr HIV Social Res, Sydney, NSW, Australia

[9] Australian Natl Univ, John Curtin Sch Med, Div Cell Biol & Immunol, Canberra, ACT, Australia

来源：

AIDS | 2006年 / 20卷 / 02期

关键词：

D O I：

10.1097/01.aids.0000199819.40079.e9

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 X 10(7) \pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.

引用

页码：294 / 297

页数：4

共 10 条

[1] Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules
Boyle, DB
Anderson, MA
Amos, R
Voysey, R
Coupar, BEH
[J]. BIOTECHNIQUES, 2004, 37 (01) : 104 - +
[2] CELL-MEDIATED IMMUNE-RESPONSE TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 IN SERONEGATIVE HOMOSEXUAL MEN WITH RECENT SEXUAL EXPOSURE TO HIV-1
CLERICI, M
GIORGI, JV
CHOU, CC
GUDEMAN, VK
ZACK, JA
GUPTA, P
HO, HN
NISHANIAN, PG
BERZOFSKY, JA
SHEARER, GM
[J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (06) : 1012 - 1019
[3] Aids vaccines - HIV dodges one-two punch
Cohen, J
[J]. SCIENCE, 2004, 305 (5690) : 1545 - +
[4] Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus
Dale, CJ
De Rose, R
Stratov, I
Chea, S
Montefiori, DC
Thomson, S
Ramshaw, IA
Coupar, BEH
Boyle, DB
Law, M
Kent, SJ
[J]. JOURNAL OF VIROLOGY, 2004, 78 (24) : 13819 - 13828
[5] Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNγ or IL-12
Dale, CJ
De Rose, R
Wilson, KM
Croom, HA
Thomson, S
Coupar, BEH
Ramsay, A
Purcell, DFJ
Ffrench, R
Law, M
Emery, S
Cooper, DA
Ramshaw, IA
Boyle, DB
Kent, SJ
[J]. VACCINE, 2004, 23 (02) : 188 - 197
[6] Haigwood Nancy L, 2003, AIDS, V17 Suppl 4, pS67, DOI 10.1097/00002030-200317004-00008
[7] Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
Kent, SJ
Zhao, A
Best, SJ
Chandler, JD
Boyle, DB
Ramshaw, IA
[J]. JOURNAL OF VIROLOGY, 1998, 72 (12) : 10180 - 10188
[8] Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know
Pantaleo, G
Koup, RA
[J]. NATURE MEDICINE, 2004, 10 (08) : 806 - 810
[9] Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
Ramsay, AJ
Kent, SJ
Strugnell, RA
Suhrbier, A
Thomson, SA
Ramshaw, IA
[J]. IMMUNOLOGICAL REVIEWS, 1999, 171 : 27 - 44
[10] HIV-SPECIFIC CYTOTOXIC T-CELLS IN HIV-EXPOSED BUT UNINFECTED GAMBIAN WOMEN
ROWLANDJONES, S
SUTTON, J
ARIYOSHI, K
DONG, T
GOTCH, F
MCADAM, S
WHITBY, D
SABALLY, S
GALLIMORE, A
CORRAH, T
TAKIGUCHI, M
SCHULTZ, T
MCMICHAEL, A
WHITTLE, H
[J]. NATURE MEDICINE, 1995, 1 (01) : 59 - 64

← 1 →